The most common solution for this situation relies on gene-expression panels, which have been successful in difficult tasks such as predicting benefit or not from hormonal treatment alone in non-HER2-positive breast cancers by grouping cancers on the basis of the expression of a number of genes47,48. The gene discussed is ERBB2; the disease is breast carcinoma.